Send to

Choose Destination
Postgrad Med. 2017 Sep;129(7):657-666. doi: 10.1080/00325481.2017.1354648. Epub 2017 Aug 1.

A clinician's guide to ADHD treatment options.

Author information

a Washington University School of Medicine , Department of Psychiatry and Behavioral Neurosciences , St. Charles , MO , USA.
b Midwest Research Group , St. Charles , MO , USA.
c Washington University School of Medicine , Division of Child and Adolescent Psychiatry , Saint Louis , MO , USA.
d University of Pennsylvania Health System , Department of Psychiatry, Office of Education , Philadelphia , PA , USA.


Attention deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition of children and adolescents that often persists into adulthood. Primary care physicians are commonly the first to diagnosis ADHD and initiate a treatment plan with the patient. Guidelines recommend psychostimulant treatment as a first-line therapy in the management plan because it has a substantial impact on alleviating the core symptoms of ADHD. The recent development of a variety of methylphenidate and amphetamine formulations provides many options to meet individual patient lifestyle needs. Liquid, chewable, sprinkled capsule, wearable patch, and orally disintegrating tablet formulations are currently available for patients who may be noncompliant with or have difficulty swallowing traditional pills. This review provides a resource for physicians to identify the stimulant delivery formulation that best suits the patient. Formulations in development are also discussed.


ADHD; amphetamine; drug delivery; methylphenidate; psychiatry; psychostimulant

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center